This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Semaglutide patent expiry exposes global split on access, exclusivity

By Freny Patel and Melissa Ritti ( April 2, 2026, 03:43 GMT | Comment) -- Semaglutide’s patent expiry has triggered global divergence, with India seeing rapid generic entry and price cuts, China promoting innovation, and the US maintaining exclusivity, forcing Novo Nordisk to adapt its strategy across sharply contrasting regulatory and market landscapes.The March 20, 2026 expiration of the "molecule patent" for semaglutide is fast becoming a defining moment for the global pharmaceutical industry, exposing stark contrasts in how major markets handle the loss of exclusivity....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections